| BCBS Federal Medical & Drug | 2.04.125 Proteomic Testing for Targeted Therapy in Non-Small-Cell Lung Cancer | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.128 Genetic Testing for Fanconi Anemia | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.131 Pharmacogenetic Testing for Pain Management | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.136 Nutrient/Nutritional Panel Testing | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.137 Genetic Testing for Neurofibromatosis | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.141 Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy) | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.147 Next-Generation Sequencing for the Assessment of Measurable Residual Disease | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.150 Serologic Genetic and Molecular Screening for Colorectal Cancer | 2026-03-01 |
| BCBS Federal Medical & Drug | 2.04.151 Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Breast Cancer (BRCA1, BRCA2, PIK3CA, Ki-67, RET, BRAF, ESR1, NTRK) | 2026-03-01 |
| BCBS Federal Medical & Drug | 6.01.26 Oncologic Applications of Positron Emission Tomography Scanning (Genitourinary) | 2026-03-01 |